Gerardo Antonio Umanzor Funez, MD, on Comparing IV and Oral Formulations of Paclitaxel – The ASCO Post

Gerardo Antonio Umanzor Funez, MD, of Liga Contra El Cáncer, discusses phase III findings on intravenous (IV) paclitaxel and oral paclitaxel plus encequidar (a novel P-gp inhibitor), the first orally administered taxane regimen shown to be superior to the IV formulation in terms of response and survival with less neuropathy (Abstract GS6-01). Javier…

Read the full article here

Related Articles